Jiawei Geng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiawei Geng has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Jie Chen
Department of Gastroenterology The Third Xiangya Hospital of Central South University Changsha Hunan China
3 shared publicationsJonas F. Ludvigsson
Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden
3 shared publicationsShuai Yuan
Department of Surgery University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
3 shared publicationsTian Fu
Department of Gastroenterology Affiliated Hangzhou First People's Hospital School of Medicine Westlake University Hangzhou Zhejiang China
3 shared publicationsErxu Xue
Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 shared publications- Jie Chen
Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, China
2 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7)
Long‐Term Multisystem Comorbidity Patterns in Acute Pancreatitis: Insights From Observational and Genetic Analysis
Introduction: Acute pancreatitis (AP) is an inflammatory pancreatic disorder with potentially severe systemic consequences. While its immediate clinical impact is well established, the long‐term multisystem comorbidities of AP remain underexplored. Clarifying the temporal sequence of these comorbidities is essential for improving patient outcomes. Methods: We conducted a phenome‐wide association study (PheWAS) to investigate the associations between AP and 1429 clinical outcomes using Cox proportional hazards models in the UK Biobank. A total of 4767 AP cases were matched 1:10 with controls through birth year, sex, and Townsend deprivation index using incidence density sampling. Disease trajectory analyses were performed to characterize sequential diagnostic patterns of AP‐associated comorbidities. Genetic approaches including polygenic risk score analysis, linkage disequilibrium score regression (LDSC), and two‐sample Mendelian randomization (TSMR) were used as a genetic triangulation framework to provide complementary evidence for the observational findings and explore shared genetic architecture and potential causal relevance. Results: Over an average follow‐up of 13.7 years, AP was associated with 250 incident comorbidities and all‐cause death. Three major temporal patterns of AP‐related comorbidities were identified, beginning with digestive diseases (e.g., chronic pancreatitis), metabolic and endocrine disorders (e.g., diabetes mellitus), as well as other systemic conditions (e.g., depression). Subsequently, increased risk of organ dysfunction such as myocardial infarction, renal failure, respiratory failure, and then dystrophia, sepsis, septicemia, acidosis followed by all‐cause death were observed. The polygenic PheWAS, LDSC, and TSMR analyses provided complementary support for selected associations, including chronic pancreatitis, cyst and pseudocyst of pancreas, duodenal ulcer, diabetes mellitus, anxiety disorder, asthma, and myocardial infarction. Conclusions: This study characterizes long‐term multisystem comorbidity patterns associated with AP, highlighting temporal diagnostic patterns linked to adverse outcomes. These findings support the need for multidisciplinary monitoring and targeted interventions to mitigate long‐term risks in AP patients.
- 18 September 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7)
Open AccessLong‐Term Multisystem Comorbidity Patterns in Acute Pancreatitis: Insights From Observational and Genetic Analysis
Introduction: Acute pancreatitis (AP) is an inflammatory pancreatic disorder with potentially severe systemic consequences. While its immediate clinical impact is well established, the long‐term multisystem comorbidities of AP remain underexplored. Clarifying the temporal sequence of these comorbidities is essential for improving patient outcomes. Methods: We conducted a phenome‐wide association study (PheWAS) to investigate the associations between AP and 1429 clinical outcomes using Cox proportional hazards models in the UK Biobank. A total of 4767 AP cases were matched 1:10 with controls through birth year, sex, and Townsend deprivation index using incidence density sampling. Disease trajectory analyses were performed to characterize sequential diagnostic patterns of AP‐associated comorbidities. Genetic approaches including polygenic risk score analysis, linkage disequilibrium score regression (LDSC), and two‐sample Mendelian randomization (TSMR) were used as a genetic triangulation framework to provide complementary evidence for the observational findings and explore shared genetic architecture and potential causal relevance. Results: Over an average follow‐up of 13.7 years, AP was associated with 250 incident comorbidities and all‐cause death. Three major temporal patterns of AP‐related comorbidities were identified, beginning with digestive diseases (e.g., chronic pancreatitis), metabolic and endocrine disorders (e.g., diabetes mellitus), as well as other systemic conditions (e.g., depression). Subsequently, increased risk of organ dysfunction such as myocardial infarction, renal failure, respiratory failure, and then dystrophia, sepsis, septicemia, acidosis followed by all‐cause death were observed. The polygenic PheWAS, LDSC, and TSMR analyses provided complementary support for selected associations, including chronic pancreatitis, cyst and pseudocyst of pancreas, duodenal ulcer, diabetes mellitus, anxiety disorder, asthma, and myocardial infarction. Conclusions: This study characterizes long‐term multisystem comorbidity patterns associated with AP, highlighting temporal diagnostic patterns linked to adverse outcomes. These findings support the need for multidisciplinary monitoring and targeted interventions to mitigate long‐term risks in AP patients.
- Open Access
- 13 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (55) , e76509
Risk of Inflammatory Bowel Disease Following Hospital‐Treated Infections and Modulatory Role of Host Genetics to Support a Multi‐Hit Pathogenesis Model
Infectious diseases can cause lasting immune disturbances, but whether they contribute to later inflammatory bowel disease (IBD) is unclear. Hospital‐treated infections may be especially informative because they reflect substantial immune challenge, yet their relation to IBD risk and the role of host genetics remain poorly defined. It examines hospital‐treated infections and incident IBD in a prospective cohort and integrates gene‐environment interaction analyses to identify susceptibility pathways and develop a post‐infection risk score. Hospital‐treated infections of multiple pathogen types and sites were associated with higher subsequent IBD risk. This association is stronger in carriers of immune‐related risk variants, with Crohn's disease linked mainly to innate immune and autophagy pathways and ulcerative colitis to JAK‐STAT, T‐cell differentiation, and chemokine signaling. An Infection IBD Score based on 44 immune‐related genes stratified post‐infection risk. These findings support infections as triggers of IBD in genetically susceptible individuals and highlight a potential tool for risk stratification.
- 13 July 2026
- Published by Wiley in Advanced Science
- Vol. 13 (55) , e76509
Open AccessRisk of Inflammatory Bowel Disease Following Hospital‐Treated Infections and Modulatory Role of Host Genetics to Support a Multi‐Hit Pathogenesis Model
Infectious diseases can cause lasting immune disturbances, but whether they contribute to later inflammatory bowel disease (IBD) is unclear. Hospital‐treated infections may be especially informative because they reflect substantial immune challenge, yet their relation to IBD risk and the role of host genetics remain poorly defined. It examines hospital‐treated infections and incident IBD in a prospective cohort and integrates gene‐environment interaction analyses to identify susceptibility pathways and develop a post‐infection risk score. Hospital‐treated infections of multiple pathogen types and sites were associated with higher subsequent IBD risk. This association is stronger in carriers of immune‐related risk variants, with Crohn's disease linked mainly to innate immune and autophagy pathways and ulcerative colitis to JAK‐STAT, T‐cell differentiation, and chemokine signaling. An Infection IBD Score based on 44 immune‐related genes stratified post‐infection risk. These findings support infections as triggers of IBD in genetically susceptible individuals and highlight a potential tool for risk stratification.
- Open Access
- 1 March 2026
- Vol. 15 (3) , e71574
Effectiveness of Continuity of Care Interventions Linking Hospital Care to Primary Healthcare for Patients With Cancer: A Systematic Review and Meta-Analysis.
The growing burden of cancer necessitates continuity of care interventions linking hospital and primary health care (PHC). However, optimal approaches for improving effectiveness and for enhancing care coordination of PHC integration remain unclear. A systematic review with meta-analysis was conducted. Six databases including PubMed, Embase, Web of Science, CINAHL, CENTRAL, and PsycInfo were searched for full texts of randomized or non-randomized controlled trials (RCTs or nRCTs) from January 2000 to January 2024. Patient-reported outcomes (quality of care, psychological status), quality of care (adverse events, perceived continuity of care, and satisfaction), healthcare utilization (hospitalization, PHC use, length of stay and emergency visits), and cost evaluation were synthesized. A random-effects model was used for data analysis, and exploratory subgroup analyses based on intervention characteristics were conducted. Risk of bias was evaluated by using Cochrane Collaboration's Risk of Bias handbooks of RCTs, or Cochrane Risk of Bias Assessment Tool for nRCTs. Intervention strategies aimed at addressing the continuity of care dimensions were synthesized through a deductive approach. Twenty eight studies from 23 unique interventions were included in the study, all conducted in high-income countries. Information continuity demonstrated the most effective practice, while management continuity received less emphasis. The overall effect size for quality of life was insignificant (standard mean difference [SMD] 0.01, 95% CI -0.04, 0.05), whereas satisfaction with care was marginally improved in intervention groups (SMD = 0.09, 95% CI 0.01, 0.18). Potential beneficial effects in reduced healthcare utilization and economic savings warrant further study. Continuity of care interventions by integrating PHC into cancer care is overall not inferior to specialist-led care. Further efforts to enhance the management continuity dimension of intervention and extend initiatives beyond high-income countries are warranted. PROSPERO registration number CRD42023473024.
- 1 March 2026
- Vol. 15 (3) , e71574
Open AccessEffectiveness of Continuity of Care Interventions Linking Hospital Care to Primary Healthcare for Patients With Cancer: A Systematic Review and Meta-Analysis.
The growing burden of cancer necessitates continuity of care interventions linking hospital and primary health care (PHC). However, optimal approaches for improving effectiveness and for enhancing care coordination of PHC integration remain unclear. A systematic review with meta-analysis was conducted. Six databases including PubMed, Embase, Web of Science, CINAHL, CENTRAL, and PsycInfo were searched for full texts of randomized or non-randomized controlled trials (RCTs or nRCTs) from January 2000 to January 2024. Patient-reported outcomes (quality of care, psychological status), quality of care (adverse events, perceived continuity of care, and satisfaction), healthcare utilization (hospitalization, PHC use, length of stay and emergency visits), and cost evaluation were synthesized. A random-effects model was used for data analysis, and exploratory subgroup analyses based on intervention characteristics were conducted. Risk of bias was evaluated by using Cochrane Collaboration's Risk of Bias handbooks of RCTs, or Cochrane Risk of Bias Assessment Tool for nRCTs. Intervention strategies aimed at addressing the continuity of care dimensions were synthesized through a deductive approach. Twenty eight studies from 23 unique interventions were included in the study, all conducted in high-income countries. Information continuity demonstrated the most effective practice, while management continuity received less emphasis. The overall effect size for quality of life was insignificant (standard mean difference [SMD] 0.01, 95% CI -0.04, 0.05), whereas satisfaction with care was marginally improved in intervention groups (SMD = 0.09, 95% CI 0.01, 0.18). Potential beneficial effects in reduced healthcare utilization and economic savings warrant further study. Continuity of care interventions by integrating PHC into cancer care is overall not inferior to specialist-led care. Further efforts to enhance the management continuity dimension of intervention and extend initiatives beyond high-income countries are warranted. PROSPERO registration number CRD42023473024.
- Open Access
- 25 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71574
Effectiveness of Continuity of Care Interventions Linking Hospital Care to Primary Healthcare for Patients With Cancer: A Systematic Review and Meta‐Analysis
Background: The growing burden of cancer necessitates continuity of care interventions linking hospital and primary health care (PHC). However, optimal approaches for improving effectiveness and for enhancing care coordination of PHC integration remain unclear. Methods: A systematic review with meta‐analysis was conducted. Six databases including PubMed, Embase, Web of Science, CINAHL, CENTRAL, and PsycInfo were searched for full texts of randomized or non‐randomized controlled trials (RCTs or nRCTs) from January 2000 to January 2024. Patient‐reported outcomes (quality of care, psychological status), quality of care (adverse events, perceived continuity of care, and satisfaction), healthcare utilization (hospitalization, PHC use, length of stay and emergency visits), and cost evaluation were synthesized. A random‐effects model was used for data analysis, and exploratory subgroup analyses based on intervention characteristics were conducted. Risk of bias was evaluated by using Cochrane Collaboration's Risk of Bias handbooks of RCTs, or Cochrane Risk of Bias Assessment Tool for nRCTs. Intervention strategies aimed at addressing the continuity of care dimensions were synthesized through a deductive approach. Results: Twenty eight studies from 23 unique interventions were included in the study, all conducted in high‐income countries. Information continuity demonstrated the most effective practice, while management continuity received less emphasis. The overall effect size for quality of life was insignificant (standard mean difference [SMD] 0.01, 95% CI −0.04, 0.05), whereas satisfaction with care was marginally improved in intervention groups (SMD = 0.09, 95% CI 0.01, 0.18). Potential beneficial effects in reduced healthcare utilization and economic savings warrant further study. Conclusions: Continuity of care interventions by integrating PHC into cancer care is overall not inferior to specialist‐led care. Further efforts to enhance the management continuity dimension of intervention and extend initiatives beyond high‐income countries are warranted. Trial Registration: PROSPERO registration number CRD42023473024
- 25 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71574
Open AccessEffectiveness of Continuity of Care Interventions Linking Hospital Care to Primary Healthcare for Patients With Cancer: A Systematic Review and Meta‐Analysis
Background: The growing burden of cancer necessitates continuity of care interventions linking hospital and primary health care (PHC). However, optimal approaches for improving effectiveness and for enhancing care coordination of PHC integration remain unclear. Methods: A systematic review with meta‐analysis was conducted. Six databases including PubMed, Embase, Web of Science, CINAHL, CENTRAL, and PsycInfo were searched for full texts of randomized or non‐randomized controlled trials (RCTs or nRCTs) from January 2000 to January 2024. Patient‐reported outcomes (quality of care, psychological status), quality of care (adverse events, perceived continuity of care, and satisfaction), healthcare utilization (hospitalization, PHC use, length of stay and emergency visits), and cost evaluation were synthesized. A random‐effects model was used for data analysis, and exploratory subgroup analyses based on intervention characteristics were conducted. Risk of bias was evaluated by using Cochrane Collaboration's Risk of Bias handbooks of RCTs, or Cochrane Risk of Bias Assessment Tool for nRCTs. Intervention strategies aimed at addressing the continuity of care dimensions were synthesized through a deductive approach. Results: Twenty eight studies from 23 unique interventions were included in the study, all conducted in high‐income countries. Information continuity demonstrated the most effective practice, while management continuity received less emphasis. The overall effect size for quality of life was insignificant (standard mean difference [SMD] 0.01, 95% CI −0.04, 0.05), whereas satisfaction with care was marginally improved in intervention groups (SMD = 0.09, 95% CI 0.01, 0.18). Potential beneficial effects in reduced healthcare utilization and economic savings warrant further study. Conclusions: Continuity of care interventions by integrating PHC into cancer care is overall not inferior to specialist‐led care. Further efforts to enhance the management continuity dimension of intervention and extend initiatives beyond high‐income countries are warranted. Trial Registration: PROSPERO registration number CRD42023473024
- Open Access
- 24 February 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Association of inflammatory bowel disease with cardiovascular disease, and the mediating role of inflammation: a matched-cohort study
Background: The elevated risk of cardiovascular disease (CVD) in inflammatory bowel disease (IBD) has been increasingly recognized. Although inflammation is implicated in both IBD and CVD, the IBD-CVD association through the mediation of systemic inflammation remains underexplored. Objective: To evaluate the associations between IBD and incident CVD and examine the mediating role of inflammatory biomarkers. Design: A sex- and age-matched cohort study. Methods: Using data from the UK Biobank, the study included 1494 participants with a first-ever diagnosis of IBD from 1999 to the recruitment date (2006–2010), and 14,940 matched reference individuals. The primary outcome was any CVD, whereas secondary outcomes included 7 major CVD categories and 19 specific CVD entities. Fifteen inflammatory biomarkers and indices measured at recruitment were included, serving as proxies of underlying inflammatory status. Cox proportional hazard model estimated the adjusted hazard ratios (HRs) and 95% confidence intervals (CI) of associations between IBD and CVD and between inflammatory biomarkers and CVD. Model-based mediation analyses were conducted to explore the potential mediating role of inflammatory biomarkers in IBD-CVD associations. Results: Compared with reference individuals, patients with IBD had an increased risk of any CVD (HR = 1.34, 95%CI 1.20, 1.49), ischemic heart disease (HR = 1.20, 95%CI 1.02, 1.41), heart failure (HR = 1.61, 95%CI 1.28, 2.02), arrhythmias (HR = 1.34, 95%CI 1.13, 1.59), atrial fibrillation (HR = 1.34, 95%CI 1.11, 1.62), other supraventricular arrhythmia (HR = 1.83, 95%CI 1.12, 2.99), and venous thromboembolism (HR = 1.74, 95%CI 1.38, 2.21). The mediation proportion was generally higher in Crohn’s disease and in CVD subtypes (ischemic heart disease, heart failure, and arrhythmias) than in venous thromboembolism. Conclusion: IBD is associated with various CVD outcomes, and inflammatory biomarkers mediate their associations, suggesting that reducing inflammation may help alleviate cardiac burden in patients with IBD.
- 24 February 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Open AccessAssociation of inflammatory bowel disease with cardiovascular disease, and the mediating role of inflammation: a matched-cohort study
Background: The elevated risk of cardiovascular disease (CVD) in inflammatory bowel disease (IBD) has been increasingly recognized. Although inflammation is implicated in both IBD and CVD, the IBD-CVD association through the mediation of systemic inflammation remains underexplored. Objective: To evaluate the associations between IBD and incident CVD and examine the mediating role of inflammatory biomarkers. Design: A sex- and age-matched cohort study. Methods: Using data from the UK Biobank, the study included 1494 participants with a first-ever diagnosis of IBD from 1999 to the recruitment date (2006–2010), and 14,940 matched reference individuals. The primary outcome was any CVD, whereas secondary outcomes included 7 major CVD categories and 19 specific CVD entities. Fifteen inflammatory biomarkers and indices measured at recruitment were included, serving as proxies of underlying inflammatory status. Cox proportional hazard model estimated the adjusted hazard ratios (HRs) and 95% confidence intervals (CI) of associations between IBD and CVD and between inflammatory biomarkers and CVD. Model-based mediation analyses were conducted to explore the potential mediating role of inflammatory biomarkers in IBD-CVD associations. Results: Compared with reference individuals, patients with IBD had an increased risk of any CVD (HR = 1.34, 95%CI 1.20, 1.49), ischemic heart disease (HR = 1.20, 95%CI 1.02, 1.41), heart failure (HR = 1.61, 95%CI 1.28, 2.02), arrhythmias (HR = 1.34, 95%CI 1.13, 1.59), atrial fibrillation (HR = 1.34, 95%CI 1.11, 1.62), other supraventricular arrhythmia (HR = 1.83, 95%CI 1.12, 2.99), and venous thromboembolism (HR = 1.74, 95%CI 1.38, 2.21). The mediation proportion was generally higher in Crohn’s disease and in CVD subtypes (ischemic heart disease, heart failure, and arrhythmias) than in venous thromboembolism. Conclusion: IBD is associated with various CVD outcomes, and inflammatory biomarkers mediate their associations, suggesting that reducing inflammation may help alleviate cardiac burden in patients with IBD.
- Open Access
- 12 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 2481
GWAS identifies genetic loci, lifestyle factors and circulating biomarkers that are risk factors for sarcoidosis
Sarcoidosis is a complex inflammatory disease with a strong genetic component. Here, we perform a genome-wide association study in 9755 sarcoidosis cases to identify risk loci and map associated genes. We then use transcriptome-wide association studies and enrichment analyses to explore pathways involved in sarcoidosis and use Mendelian randomization to examine associations with modifiable factors and circulating biomarkers. We identify 28 genomic loci associated with sarcoidosis, with the C1orf141-IL23R locus showing the largest effect size. We observe gene expression patterns related to sarcoidosis in the spleen, whole blood, and lung, and highlight 75 tissue-specific genes through transcriptome-wide association studies. Furthermore, we use enrichment analysis to establish key roles for T cell activation, leukocyte adhesion, and cytokine production in sarcoidosis. Additionally, we find associations between sarcoidosis and genetically predicted body mass index, interleukin-23 receptor, and eight circulating proteins.
- 12 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 2481
Open AccessGWAS identifies genetic loci, lifestyle factors and circulating biomarkers that are risk factors for sarcoidosis
Sarcoidosis is a complex inflammatory disease with a strong genetic component. Here, we perform a genome-wide association study in 9755 sarcoidosis cases to identify risk loci and map associated genes. We then use transcriptome-wide association studies and enrichment analyses to explore pathways involved in sarcoidosis and use Mendelian randomization to examine associations with modifiable factors and circulating biomarkers. We identify 28 genomic loci associated with sarcoidosis, with the C1orf141-IL23R locus showing the largest effect size. We observe gene expression patterns related to sarcoidosis in the spleen, whole blood, and lung, and highlight 75 tissue-specific genes through transcriptome-wide association studies. Furthermore, we use enrichment analysis to establish key roles for T cell activation, leukocyte adhesion, and cytokine production in sarcoidosis. Additionally, we find associations between sarcoidosis and genetically predicted body mass index, interleukin-23 receptor, and eight circulating proteins.
- Open Access
- 26 November 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (2) , 866-875
Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease
Aims: The molecular mechanisms underlying the association between type 2 diabetes (T2D) and gastrointestinal (GI) disease are unclear. To identify protein pathways, we conducted a two‐stage network Mendelian randomisation (MR) study. Materials and Methods: Genetic instruments for T2D were obtained from a large‐scale summary‐level genome‐wide meta‐analysis. Genetic associations with blood protein levels were obtained from three genome‐wide association studies on plasma proteins (i.e. the deCODE study as the discovery and the UKB‐PPP and Fenland studies as the replication). Summary‐level data on 10 GI diseases were derived from genome‐wide meta‐analysis of the UK Biobank and FinnGen. MR and colocalisation analyses were performed. Pathways were constructed according to the directionality of total and indirect effects, and corresponding proportional mediation was estimated. Druggability assessments were conducted across four databases to prioritise protein mediators. Results: Genetic liability to T2D was associated with 69 proteins in the discovery protein dataset after multiple testing corrections. All associations were replicated at the nominal significance level. Among T2D‐associated proteins, genetically predicted levels of nine proteins were associated with at least one of the GI diseases. Genetically predicted levels of SULT2A1 (odds ratio = 1.98, 95% CI 1.80–2.18), and ADH1B (odds ratio = 2.05, 95% CI 1.43–2.94) were associated with cholelithiasis and cirrhosis respectively. SULT2A1 and cholelithiasis (PH4 = 0.996) and ADH1B and cirrhosis (PH4 = 0.931) have strong colocalisation support, accounting for the mediation proportion of 72.8% (95% CI 45.7–99.9) and 42.9% (95% CI 15.5–70.4) respectively. Conclusions: The study identified some proteins mediating T2D‐GI disease associations, which provided biological insights into the underlying pathways.
- 26 November 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (2) , 866-875
Open AccessNetwork Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease
Aims: The molecular mechanisms underlying the association between type 2 diabetes (T2D) and gastrointestinal (GI) disease are unclear. To identify protein pathways, we conducted a two‐stage network Mendelian randomisation (MR) study. Materials and Methods: Genetic instruments for T2D were obtained from a large‐scale summary‐level genome‐wide meta‐analysis. Genetic associations with blood protein levels were obtained from three genome‐wide association studies on plasma proteins (i.e. the deCODE study as the discovery and the UKB‐PPP and Fenland studies as the replication). Summary‐level data on 10 GI diseases were derived from genome‐wide meta‐analysis of the UK Biobank and FinnGen. MR and colocalisation analyses were performed. Pathways were constructed according to the directionality of total and indirect effects, and corresponding proportional mediation was estimated. Druggability assessments were conducted across four databases to prioritise protein mediators. Results: Genetic liability to T2D was associated with 69 proteins in the discovery protein dataset after multiple testing corrections. All associations were replicated at the nominal significance level. Among T2D‐associated proteins, genetically predicted levels of nine proteins were associated with at least one of the GI diseases. Genetically predicted levels of SULT2A1 (odds ratio = 1.98, 95% CI 1.80–2.18), and ADH1B (odds ratio = 2.05, 95% CI 1.43–2.94) were associated with cholelithiasis and cirrhosis respectively. SULT2A1 and cholelithiasis (PH4 = 0.996) and ADH1B and cirrhosis (PH4 = 0.931) have strong colocalisation support, accounting for the mediation proportion of 72.8% (95% CI 45.7–99.9) and 42.9% (95% CI 15.5–70.4) respectively. Conclusions: The study identified some proteins mediating T2D‐GI disease associations, which provided biological insights into the underlying pathways.
- Open Access
- 2 February 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04033
Global, regional, and national burden and quality of care of multiple myeloma, 1990–2019
Multiple myeloma (MM), which manifests as unregulated clonal plasma cell proliferation in the bone marrow, is the second most common clonal plasma cell cancer (plasma cancer evolved through reiterative clonal expansion), accounting for around 10% of all haematologic malignancies [1–3]. Up to 63% of diagnosed patients are >65 years old [4]. The alterations in the […]
- 2 February 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04033
Open AccessGlobal, regional, and national burden and quality of care of multiple myeloma, 1990–2019
Multiple myeloma (MM), which manifests as unregulated clonal plasma cell proliferation in the bone marrow, is the second most common clonal plasma cell cancer (plasma cancer evolved through reiterative clonal expansion), accounting for around 10% of all haematologic malignancies [1–3]. Up to 63% of diagnosed patients are >65 years old [4]. The alterations in the […]
- Open Access
- 27 October 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (10) , e38624
Effectiveness of Computerized Cognitive Training in Delaying Cognitive Function Decline in People With Mild Cognitive Impairment: Systematic Review and Meta-analysis
Background: With no current cure for mild cognitive impairment (MCI), delaying its progression could significantly reduce the disease burden and improve the quality of life for patients with MCI. Computerized cognitive training (CCT) has recently become a potential instrument for improvement of cognition. However, the evidence for its effectiveness remains limited. Objective: This systematic review aims to (1) analyze the efficacy of CCT on cognitive impairment or cognitive decline in patients with MCI and (2) analyze the relationship between the characteristics of CCT interventions and cognition-related health outcomes. Methods: A systematic search was performed using MEDLINE, Cochrane, Embase, Web of Science, and Google Scholar. Full texts of randomized controlled trials of CCT interventions in adults with MCI and published in English language journals between 2010 and 2021 were included. Overall global cognitive function and domain-specific cognition were pooled using a random-effects model. Sensitivity analyses were performed to determine the reasons for heterogeneity and to test the robustness of the results. Subgroup analyses were performed to identify the relationship between the characteristics of CCT interventions and cognition-related effectiveness. Results: A total of 18 studies with 1059 participants were included in this review. According to the meta-analysis, CCT intervention provided a significant but small increase in global cognitive function compared to that in the global cognitive function of the control groups (standardized mean difference=0.54, 95% CI 0.35-0.73; I2=38%). CCT intervention also resulted in a marginal improvement in domain-specific cognition compared to that in the control groups, with moderate heterogeneity. Subgroup analyses showed consistent improvement in global cognitive behavior in the CCT intervention groups. Conclusions: This systematic review suggests that CCT interventions could improve global cognitive function in patients with MCI. Considering the relatively small sample size and the short treatment duration in all the included studies, more comprehensive trials are needed to quantify both the impact of CCT on cognitive decline, especially in the longer term, and to establish whether CCT should be recommended for use in clinical practice. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021278884; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278884
- 27 October 2022
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 24 (10) , e38624
Open AccessEffectiveness of Computerized Cognitive Training in Delaying Cognitive Function Decline in People With Mild Cognitive Impairment: Systematic Review and Meta-analysis
Background: With no current cure for mild cognitive impairment (MCI), delaying its progression could significantly reduce the disease burden and improve the quality of life for patients with MCI. Computerized cognitive training (CCT) has recently become a potential instrument for improvement of cognition. However, the evidence for its effectiveness remains limited. Objective: This systematic review aims to (1) analyze the efficacy of CCT on cognitive impairment or cognitive decline in patients with MCI and (2) analyze the relationship between the characteristics of CCT interventions and cognition-related health outcomes. Methods: A systematic search was performed using MEDLINE, Cochrane, Embase, Web of Science, and Google Scholar. Full texts of randomized controlled trials of CCT interventions in adults with MCI and published in English language journals between 2010 and 2021 were included. Overall global cognitive function and domain-specific cognition were pooled using a random-effects model. Sensitivity analyses were performed to determine the reasons for heterogeneity and to test the robustness of the results. Subgroup analyses were performed to identify the relationship between the characteristics of CCT interventions and cognition-related effectiveness. Results: A total of 18 studies with 1059 participants were included in this review. According to the meta-analysis, CCT intervention provided a significant but small increase in global cognitive function compared to that in the global cognitive function of the control groups (standardized mean difference=0.54, 95% CI 0.35-0.73; I2=38%). CCT intervention also resulted in a marginal improvement in domain-specific cognition compared to that in the control groups, with moderate heterogeneity. Subgroup analyses showed consistent improvement in global cognitive behavior in the CCT intervention groups. Conclusions: This systematic review suggests that CCT interventions could improve global cognitive function in patients with MCI. Considering the relatively small sample size and the short treatment duration in all the included studies, more comprehensive trials are needed to quantify both the impact of CCT on cognitive decline, especially in the longer term, and to establish whether CCT should be recommended for use in clinical practice. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021278884; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278884